These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Deacon AC; Peters TJ Ann Clin Biochem; 1998 Nov; 35 ( Pt 6)():726-32. PubMed ID: 9838985 [TBL] [Abstract][Full Text] [Related]
3. Screening tests for porphobilinogen are insensitive. The problem and its solution. Schreiber WE; Jamani A; Pudek MR Am J Clin Pathol; 1989 Nov; 92(5):644-9. PubMed ID: 2816816 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the Hoesch and the Watson-Schwartz tests for urinary porphobilinogen. Pierach CA; Cardinal R; Bossenmaier I; Watson CJ Clin Chem; 1977 Sep; 23(9):1666-8. PubMed ID: 890911 [TBL] [Abstract][Full Text] [Related]
5. Best practice guidelines on first-line laboratory testing for porphyria. Woolf J; Marsden JT; Degg T; Whatley S; Reed P; Brazil N; Stewart MF; Badminton M Ann Clin Biochem; 2017 Mar; 54(2):188-198. PubMed ID: 27555665 [TBL] [Abstract][Full Text] [Related]
6. The Hoesch test: bedside screening for urinary porphobilinogen in patients with suspected porphyria. Lamon J; With TK; Redeker AG Clin Chem; 1974 Nov; 20(11):1438-40. PubMed ID: 4425514 [No Abstract] [Full Text] [Related]
7. Liquid-chromatographic assay of urinary porphobilinogen. Jamani A; Pudek M; Schreiber WE Clin Chem; 1989 Mar; 35(3):471-5. PubMed ID: 2920415 [TBL] [Abstract][Full Text] [Related]
8. A sensitive method of screening for urinary porphobilinogen. Buttery JE; Chamberlain BR; Beng CG Clin Chem; 1989 Dec; 35(12):2311-2. PubMed ID: 2591048 [TBL] [Abstract][Full Text] [Related]
9. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria. Marsden JT; Rees DC J Clin Pathol; 2014 Jan; 67(1):60-5. PubMed ID: 23908454 [TBL] [Abstract][Full Text] [Related]
10. Rapid quantitative method using spin columns to measure porphobilinogen in urine. Roshal M; Turgeon J; Rainey PM Clin Chem; 2008 Feb; 54(2):429-31. PubMed ID: 18223134 [TBL] [Abstract][Full Text] [Related]
11. A LC-MS/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen. Zhang J; Yasuda M; Desnick RJ; Balwani M; Bishop D; Yu C J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2389-96. PubMed ID: 21783436 [TBL] [Abstract][Full Text] [Related]
12. Simple and rapid screening for acute porphyria--'porphobilistix' and Hoesch test. With TK S Afr Med J; 1971 Sep; ():229-30. PubMed ID: 5150285 [No Abstract] [Full Text] [Related]
13. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks. Sardh E; Harper P; Andersson DE; Floderus Y Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613 [TBL] [Abstract][Full Text] [Related]
14. Individualized workup: a new approach to the biochemical diagnosis of acute attacks of neuroporphyria. Schoenfeld N; Mamet R Physiol Res; 2006; 55 Suppl 2():S103-108. PubMed ID: 17298214 [TBL] [Abstract][Full Text] [Related]
15. Direct and simultaneous determination of 5-aminolaevulinic acid and porphobilinogen in urine by hydrophilic interaction liquid chromatography-electrospray ionisation/tandem mass spectrometry. Benton CM; Couchman L; Marsden JT; Rees DC; Moniz C; Lim CK Biomed Chromatogr; 2012 Aug; 26(8):1033-40. PubMed ID: 22740490 [TBL] [Abstract][Full Text] [Related]
16. Reliability of the porphobilinogen screening assay. Buttery JE; Carrera AM; Pannall PR Pathology; 1990 Oct; 22(4):197-8. PubMed ID: 2091000 [TBL] [Abstract][Full Text] [Related]
17. Mass spectrometric characterisation of a condensation product between porphobilinogen and indolyl-3-acryloylglycine in urine of patients with acute intermittent porphyria. Marcos J; Ibañez M; Ventura R; Segura J; To-Figueras J; Pozo OJ J Mass Spectrom; 2015 Jul; 50(7):929-37. PubMed ID: 26349648 [TBL] [Abstract][Full Text] [Related]
18. Porphobilinogen-synthase (delta-aminolevulinic acid dehydratase) deficiency in bone marrow cells of two patients with porphobilinogen-synthase defect acute porphyria. Doss M; Tiepermann RV; Schneider J Klin Wochenschr; 1983 Jul; 61(14):699-702. PubMed ID: 6887758 [TBL] [Abstract][Full Text] [Related]
19. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Aarsand AK; Petersen PH; Sandberg S Clin Chem; 2006 Apr; 52(4):650-6. PubMed ID: 16595824 [TBL] [Abstract][Full Text] [Related]
20. Manifestation of acute intermittent porphyria in patients with chronic inflammatory bowel disease. Sieg I; Beckh K; Kersten U; Doss MO Z Gastroenterol; 1991 Nov; 29(11):602-5. PubMed ID: 1771936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]